Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. 5-Azacytidine in myelodysplastic syndromes: a clinical practice guideline.

    ... of hematopoiesis that results in peripheral blood cytopenias and a marked propensity to progress to acute myelogenous ... Although supportive or palliative measures such as blood transfusion have long been the mainstay of management of MDS, ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... 16 weeks, respectively. RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in the ...

    Research Article last updated 07/20/2018 - 5:15pm.

  4. Pathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes.

    ... to this approach. Patients may require frequent blood and platelet transfusion support which is expensive and inconvenient. Life-threatening ... agents can provide a new therapeutic option for enhancing blood production. In this review, we discuss these recent results and ongoing ...

    Research Article last updated 07/20/2018 - 5:15pm.

  5. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab

    ... Journal Title:  Blood Primary Author:  ... six patients received at least one red blood cell transfusion . Lack of detectable CH50 activity (defined by CH50 ≤10% of ...

    Research Article last updated 07/20/2018 - 5:15pm.

  6. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

    ... Journal Title:  Blood Primary Author:  ... , presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (all P < 10(-4)) independently ...

    Research Article last updated 07/20/2018 - 5:14pm.

  7. Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes

    ... Overall Response (complete or partial remission, red blood cell [RBC] or platelet transfusion independence [TI], or hematologic improvement, (IWG 2006) was ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Therapy for aplastic anemia

    ... in the unrelated donor registry, including cord blood. He is red cell- and platelet transfusion -dependent. He has been recommended therapy with ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... Journal Title:  Blood Primary Author:  ... the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 ...

    Research Article last updated 07/20/2018 - 5:14pm.

  10. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6months in the ESA and ... and duration, and of our proposed azacitidine risk score (Blood 2011;117:403-11). Adding an ESA to azacitidine in higher-risk MDS should ...

    Research Article last updated 07/20/2018 - 5:14pm.